Tempest Therapeutics, Inc. is a clinical-stage biotechnology company moving towards late-stage development with a portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class to treat a range of cancers. Its programs range from early research to the lead program, amezalpat, a pivotal study in first-line hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, is a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 (PGE2), a pathway implicated in multiple cancers. Its development strategy for TPST-1495 includes evaluation in familial adenomatous polyposis (FAP), a rare genetic disorder that increases the risk of gastrointestinal cancers. Its pipeline also includes TPST-2003, TPST-2206, TPST-3003, and TPST-3206. TPST-2003 is a new dual-targeting CD19/BCMA CAR-T asset. TPST-2206 is a dual-targeting CD70/CD70 CAR-T for renal cell carcinoma. TPST-3206 is an allogeneic dual-targeting CD70/CD70.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
23/10/26	$0.5110	-2.16%	52,253
22/10/26	$0.5223	-1.12%	195,960
21/10/26	$0.5282	-8.33%	372,889
20/10/26	$0.5762	-3.98%	144,971
19/10/26	$0.6001	-3.86%	128,474

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.5110USD

Average target price

7.000USD

Spread / Average Target

+1,269.86%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Tempest Therapeutics, Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Tempest Therapeutics, Inc.

Company calendar

Market Closed - Nasdaq 00:00:00 24/10/2026 +04			5-day change	1st Jan Change
0.5110 ^USD	-2.16%		-18.14%	-82.20%

10-14	Tempest Therapeutics, Inc. Announces Appointment of John W. Frederick as Director	CI
10-07	Sensorion: Louis J. Arcudi III appointed chief financial officer

Market Cap	8.45M 7.55M 6.97M 6.32M 11.82M 802M 12.02M 83.9M 33.22M 420M 31.72M 31.04M 1.33B	P/E 2026 *	-0.18x	P/E 2027 *	-0.57x
Enterprise Value	8.45M 7.55M 6.97M 6.32M 11.82M 802M 12.02M 83.9M 33.22M 420M 31.72M 31.04M 1.33B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	69.93%	Yield 2026 *	-	Yield 2027 *	-

10-14	Tempest Therapeutics, Inc. Announces Appointment of John W. Frederick as Director	CI
10-07	Sensorion: Louis J. Arcudi III appointed chief financial officer
09-29	Tempest Therapeutics, Inc. Announces CFO Changes, Effective September 22, 2026	CI
09-29	Tempest Therapeutics, Inc. Appoints Constance Ames as Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary, Effective September 22, 2026	CI
09-23	Tempest Therapeutics, Inc. Announces Appointment of Nancy Freda-Smith to Its Board of Director and Chair of Audit Committee, Effective September 22, 2026	CI
09-16	Top Premarket Gainers	MT
09-16	Tempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang	MT
09-15	Tempest Therapeutics, Inc. announced that it has received $2.496895 million in funding	CI
09-11	Tempest Therapeutics, Inc. announced that it expects to receive $2.500001 million in funding	CI
08-25	Tempest Therapeutics, Inc. Appoints Nicholas Rossettos as Chief Financial Officer, Effective September 1, 2026	CI
08-25	Tempest Therapeutics, Inc. Announces Executive Changes, Effective September 1, 2026	CI
08-14	Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-23	Tempest Therapeutics, Inc. and Heibei Senlang Biotechnology Co., Ltd. Enter into Product Development and Investigator-Initiated Trial Collaboration Agreement	CI

01-22	HC Wainwright Upgrades Tempest Therapeutics to Buy From Neutral, Price Target is $11	MT
10/04/25	HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy	MT
14/03/24	Scotiabank Initiates Tempest Therapeutics With Sector Outperform Rating, Price Target is $13	MT
11/10/23	HC Wainwright Raises Price Target on Tempest Therapeutics to $47 From $35, Maintains Buy Rating	MT
23/03/23	Piper Sandler Adjusts Tempest Therapeutics' Price Target to $6 From $10, Keeps Overweight Rating	MT

Tempest Therapeutics, Inc. Stock

Stocks

TPST

US87978U2078

Biotechnology & Medical Research

Valuation: Tempest Therapeutics, Inc.

Chart: Tempest Therapeutics, Inc.

Latest news: Tempest Therapeutics, Inc.

Analysts' recommendations: Tempest Therapeutics, Inc.

Press Releases: Tempest Therapeutics, Inc.

News in other languages: Tempest Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Tempest Therapeutics, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

09-23	Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors	AQ
09-16	Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform	AQ
09-11	Tempest Therapeutics Announces Up to $7.5 Million Private Placement	AQ
09-08	Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
08-14	Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update	AQ

10-07	Sensorion : Louis J. Arcudi III nommé directeur financier
20/06/24	Aktien New York Ausblick: Weitere Tech-Rekorde - Nasdaq 100 mit 20 000 Punkten

1 day	-2.16%
1 week	-18.14%
Current month	-38.75%
1 month	-39.88%
3 months	-44.81%
6 months	-71.45%
Current year	-82.20%

1 week	0.5	0.64
1 month	0.5	0.85
Current year	0.5	3.15
1 year	0.5	11.13
3 years	0.5	78
5 years	0.5	162.5
10 years	0.5	533

Manager	Title	Age	Since
Andrew Fang PRN	Corporate Officer/Principal	-	14/04/2026
Matthew Angel CEO	Chief Executive Officer	45	03/02/2026
Constance Ames DFI	Director of Finance/CFO	40	22/09/2026

Director	Title	Age	Since
Mike Raab CHM	Chairman	61	01/01/2021
Christine Pellizzari BRD	Director/Board Member	58	01/07/2021
Matthew Angel BRD	Director/Board Member	45	03/02/2026

Date	Insider	Type	Main position	Quantity	% Market Cap.
22/09/26	Nancy Freda-Smith	Free	Director	25,000	0.1854%
31/03/26	Justin Trojanowski	Free	Controller/Auditor	22,000	0.1632%
31/03/26	Nicholas Maestas	Free	Chief Financial Officer	140,000	1.0385%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TEMPEST THERAPEUTICS, INC.	-2.16%	-18.14%	-95.22%	-99.05%	8.45M
WUXI APPTEC CO., LTD.	+2.41%	+0.29%	+39.41%	+72.14%	64.69B
ARGENX SE	-0.15%	+7.50%	+11.42%	+71.27%	54.78B
LONZA GROUP AG	+0.57%	+4.60%	+7.71%	+90.93%	53.49B
IQVIA HOLDINGS INC.	+0.37%	+4.67%	+26.68%	+49.64%	45.98B
BEONE MEDICINES AG	-1.21%	+2.32%	+21.50%	+118.33%	42.94B
REVOLUTION MEDICINES, INC.	-0.37%	+5.07%	+243.23%	+789.58%	40.08B
CELLTRION, INC.	+0.05%	+0.21%	+18.06%	+48.50%	33.52B
WUXI BIOLOGICS (CAYMAN) INC.	+1.19%	-4.98%	+26.31%	-0.76%	23.97B
GENMAB A/S	-0.38%	+5.68%	+38.39%	+28.35%	23.67B
Average	+0.03%	+0.40%	+33.75%	+116.89%	38.31B
Weighted average by Cap.	+0.39%	+2.73%	+46.01%	+142.83%

Markets		Quality
Nasdaq	TPST	Delayed
CBOE	TPST	Real-time

	2026 *	2027 *
Net sales	-	-
Net income	-	-
Net Debt	-	-